Smart Digital Nudges Boost GLP-1 Healthy Habits

What Are Digital Microsteps for GLP-1 Users?

GLP-1 medications like Ozempic and Mounjaro have transformed weight management. Yet medication alone does not complete the picture. A new Stanford Medicine study suggests that tiny, digitally delivered behavioral nudges — known as microsteps — can drive GLP-1 users toward meaningful lifestyle improvements.

Maya Adam, MD, PhD, director of health media innovation and a clinical associate professor in pediatrics at Stanford Medicine, led the research. “Achieving your best health involves a lot more than pharmacotherapy alone,” she said. “Giving people these little nudges may be very effective.”

Moreover, the concept of microsteps draws from Arianna Huffington’s Thrive Global framework. Developers there describe them as behaviors “too small to fail.” Examples from the study include: schedule movement time, include protein at each meal, swap sugary drinks for water, and go outside for five minutes without devices.

Why Microsteps Work for Behavior Change

The Science Behind Small Shifts

Health experts have long struggled to help patients change daily behaviors. Eating well, exercising regularly, managing stress, and sleeping enough all matter deeply for long-term health. However, physicians rarely have the time or the scalable tools to address these issues effectively.

Microsteps offer a solution. Instead of demanding sweeping lifestyle overhauls, they ask patients to make one tiny tweak at a time. Crucially, research suggests that small changes are far more likely to stick than large ones. Furthermore, digital delivery makes these nudges accessible at scale — reaching patients across countries and time zones.

Animated Videos as a Delivery Tool

Adam’s team combined microstep messaging with animated storytelling videos — a format she specializes in. Together, these two tools created a compelling, digestible package. As a result, participants in the multicountry, randomized controlled trial showed strong receptiveness to adopting new habits.

How GLP-1 Users Became the Target Audience

GLP-1 use has risen sharply — not just in the United States, but globally. The evidence for these medications keeps growing. Even so, they are not a complete solution on their own.

Interestingly, GLP-1 medications may also create the right psychological conditions for behavior change. “In many cases, GLP-1s may reframe how people view their health,” Adam explained. When patients begin to feel they are winning with medication, they often feel ready to win in other areas too. That motivational momentum is precisely the window microsteps aim to capture.

What the Stanford Study Found

Measuring Proximal Indicators

The study measured what researchers call proximal indicators — early signals that predict whether long-term change is likely. Specifically, the team tracked two closely related but distinct metrics: behavioral intention and behavioral expectation.

Behavioral intention refers to a patient’s plan to adopt a new habit. Behavioral expectation, however, accounts for real-world barriers to that plan. Researchers therefore consider behavioral expectation a stronger predictor of lasting change.

The trial results showed that microstep interventions increased participants’ behavioral expectation. This outcome, while not the end goal itself, signals that the approach is worth pursuing further. Additionally, collaborator Fatima Rodriguez, MD, MPH, associate professor of cardiovascular medicine and associate director of the Stanford Center for Digital Health, has conducted follow-up interviews with GLP-1 patients across 15 U.S. states to deepen these insights.

What Comes Next for Microstep Research

Long-Term Studies and Dosing Questions

The current findings open the door to richer, longer-term research. Next, Adam’s team plans to investigate how many microsteps patients need, how much variety works best, and how often nudges should arrive. These dosing questions matter because too few nudges may not sustain momentum, while too many could overwhelm users.

Extending the Research Timeline

Researchers will then track behavior change at three months, six months, and potentially one year. This extended timeline will help reveal whether microsteps do more than boost intention — whether they produce real, measurable shifts in how GLP-1 users eat, move, sleep, and manage stress.

Ultimately, the goal is to embed microstep prescriptions into the standard care pathways for GLP-1 patients. Given the global rise in GLP-1 prescriptions, a scalable, low-cost digital tool for behavior change could benefit millions of people worldwide. As Adam put it: “It’s an exciting time to be doing this work.”